Hypersensitivity News and Research

RSS

Hypersensitivity is an exaggerated response by the immune system to a drug or other substance.

Boehringer Ingelheim updates HCPs, patients on COMBIVENT RESPIMAT Inhalation Spray

As part of the company's commitment to chronic obstructive pulmonary disease patients, Boehringer Ingelheim Pharmaceuticals, Inc., a leader in respiratory health, is updating healthcare professionals and patients that the transition to COMBIVENT RESPIMAT (ipratropium bromide and albuterol) Inhalation Spray for the maintenance treatment of COPD is nearly complete.

18 May 2013

Researchers identify clue to explain the reversible memory loss caused by statins

The U.S. Food and Drug Administration and physicians continue to document that some patients experience fuzzy thinking and memory loss while taking statins, a class of global top-selling cholesterol-lowering drugs.

13 May 2013

Study: Hypersensitivity to motion may provide clues to fundamental cause of autism

Children with autism see simple movement twice as quickly as other children their age, and this hypersensitivity to motion may provide clues to a fundamental cause of the developmental disorder, according to a new study.

9 May 2013

Protein tumor necrosis factor-alpha is a powerful weapon to control cancer

The protein tumor necrosis factor-alpha (TNF-alpha) is a powerful weapon in the arsenal to control cancer. Unfortunately, as is the case with many potent cancer therapies, the use of TNF-alpha as an anti-cancer therapy has been severely limited.

8 May 2013

Peripheral neuropathic pain patch treatments: an interview with Anne Hodgkins, Astellas Pharma

Peripheral neuropathic pain is caused by lesion or disease to the peripheral somatosensory nervous system. Nerve damage that can lead to peripheral neuropathic pain can happen as a result of a range of different diseases, medications or traumatic injuries.

8 May 2013

Immunoglobulin fails to meet co-primary endpoints in Phase III clinical study, Baxter reports

Baxter International Inc. today announced that its Phase III clinical study of immunoglobulin did not meet its co-primary endpoints of reducing cognitive decline and preserving functional abilities in patients with mild to moderate Alzheimer's disease.

From Baxter International Inc. 8 May 2013

Study; Media reports about supposedly hazardous substances may trigger nocebo effect in some people

Media reports about substances that are supposedly hazardous to health may cause suggestible people to develop symptoms of a disease even though there is no objective reason for doing so.

7 May 2013

Martindale Pharma announces UK launch of Prenoxad Injection for opioid overdose

Martindale Pharma, a leader in the manufacture and supply of specialty pharmaceuticals, is pleased to announce the UK launch of Prenoxad Injection, the world's first licensed emergency treatment for acute opioid related overdose for use at home or other non-medical settings.

3 May 2013

Researchers identify genetic mutation linked to a typical form of migraine

A research team led by a Howard Hughes Medical Institute investigator at the University of California, San Francisco has identified a genetic mutation that is strongly associated with a typical form of migraine.

2 May 2013

Exclusion diet boosts anal fissure healing

Research published in the American Journal of Gastroenterology shows that an exclusion diet combined with medical treatment can increase healing rates in patients with chronic anal fissure who have been referred for surgery.

30 Apr 2013

Merck, Pfizer sign collaboration agreement for development and commercialization of ertugliflozin

Merck & Co., Inc., known as MSD outside the United States and Canada, and Pfizer Inc. today announced that they have entered into a worldwide (except Japan) collaboration agreement for the development and commercialization of Pfizer's ertugliflozin (PF-04971729), an investigational oral sodium glucose cotransporter (SGLT2) inhibitor being evaluated for the treatment of type 2 diabetes.

From Pfizer, Inc. 30 Apr 2013

Dyax reports Q1 2013 financial results; LFRP portfolio continues to be a growth driver

Dyax Corp. today announced financial results for the first quarter ended March 31, 2013. The Company will host a webcast and conference call at 5:00 p.m. (ET) today to review financial results and updates regarding its key value drivers - the KALBITOR® (ecallantide) business, the broader angioedema portfolio and the Licensing and Funded Research Program (LFRP).

26 Apr 2013

Data from MK-5172 Phase II study for treatment of HCV genotype 1 infection to be presented at EASL meeting

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of the latest interim data from a Phase II, multi-center, randomized, dose-ranging clinical trial evaluating the safety and antiviral activity of MK-5172, for the treatment of chronic hepatitis C virus genotype 1 infection.

24 Apr 2013

Navidea presents Phase 3 Lymphoseek study results at international symposium in Athens

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that a presentation of results from its Phase 3 clinical trial of Lymphoseek (technetium 99m tilmanocept) Injection in patients with head and neck squamous cell carcinoma received the 1st Investigator Award at the 2nd InternationaI Symposium on Thoracic and Upper Aerodigestive Malignancies.

15 Apr 2013

New data on Merck’s VICTRELIS for chronic HCV to be presented at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced today that two analyses of VICTRELIS (boceprevir) and data from Phase II studies of two of Merck's investigational medicines for chronic hepatitis C virus (HCV) genotype 1, MK-5172 and vaniprevir (MK-7009), will be presented at the 2013 International Liver Congress (EASL) Annual Meeting.

11 Apr 2013

FDA accepts Merck's NDA for NOXAFIL tablets

Merck, known as MSD outside the United States and Canada, today announced that its New Drug Application for an investigational, tablet formulation of the company's antifungal agent, NOXAFIL (posaconazole), has been accepted for review by the U.S. Food and Drug Administration.

11 Apr 2013

Study offers new insights into how nervous system processes hot and cold temperatures

A study from the University of North Carolina School of Medicine offers new insights into how the nervous system processes hot and cold temperatures. The research led by neuroscientist Mark J. Zylka, PhD, associate professor of cell biology and physiology, found an interaction between the neural circuits that detect hot and cold stimuli: cold perception is enhanced when nerve circuitry for heat is inactivated.

9 Apr 2013